Last reviewed: June 11, 2026

Last updated: June 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Choosing between weight loss medications can feel overwhelming when options carry different price tags, mechanisms of action, and clinical track records. Contrave combines naltrexone and bupropion to address appetite and metabolism through the brain's reward pathways, while Ozempic (semaglutide) activates GLP-1 receptors throughout the body to regulate blood sugar and appetite. Understanding how these treatments work—and what alternatives exist—helps you make an informed decision aligned with your health goals.

How Contrave and Ozempic Work Differently

Contrave operates through a combination approach: naltrexone blocks opioid receptors in the hypothalamus (your brain's appetite control center), while bupropion stimulates the release of appetite-suppressing neurotransmitters like norepinephrine and dopamine. This dual-action oral tablet targets the central nervous system to reduce hunger signals and increase feelings of fullness. Clinical trials show Contrave-treated patients lost approximately 5–9% of body weight over 56 weeks.

Ozempic delivers semaglutide—a GLP-1 receptor agonist—via weekly injection. Semaglutide mimics glucagon-like peptide-1, a hormone that regulates blood sugar, slows gastric emptying, and activates satiety centers in the brain. In cardiovascular outcome trials, semaglutide-treated patients achieved 10–15% body weight reductions, with additional benefits for heart health and blood sugar control. The injectable route ensures consistent dosing and allows the medication to reach systemic GLP-1 receptors more directly than oral formulations.

Effectiveness and Weight Loss Outcomes

Head-to-head comparisons show GLP-1 medications like semaglutide generally produce greater weight loss than Contrave. A meta-analysis of randomized trials found semaglutide users lost 10–15% of starting body weight, compared to 5–9% for Contrave users, over similar timeframes. Semaglutide's advantage stems partly from its ability to reduce appetite, slow digestion, and improve insulin sensitivity simultaneously across multiple organ systems.

Individual results vary significantly based on genetics, lifestyle adherence, and metabolic factors. Some patients respond better to combination oral therapy, while others achieve superior results with GLP-1 activation. PlexusDx's Precision Peptide Genetic Test identifies genetic variants in GLP1R, GIPR, FTO, and MC4R pathways that predict medication responsiveness, helping you choose the approach most likely to work for your unique biology.

Cost, Access, and Treatment Options

Contrave typically costs $150–$200 per month through traditional insurance or retail pharmacy routes. Ozempic brand-name injections often exceed $900–$1,300 monthly without insurance, though generic and compounded versions reduce this burden significantly. PlexusDx compounded semaglutide injections start at $149 per month flat—no membership fees, no insurance required—and remain available across all 50 states. Because PlexusDx sources from licensed 503A compounding pharmacies, doses can be personalized without price increases as your treatment progresses.

Beyond semaglutide injections, PlexusDx offers compounded tirzepatide (a dual GIP/GLP-1 receptor agonist) starting at $249 per month, oral semaglutide at $249 monthly, and combination protocols like GLP-Squared for patients seeking synergistic effects. All medications qualify for HSA and FSA accounts, expanding affordability. PlexusDx's Precision Peptide Genetic Test ($99 add-on) helps determine which compound and pathway best matches your genetic profile, reducing trial-and-error medication cycling.

Side Effects, Safety, and Long-Term Tolerability

Contrave's most common side effects include nausea, constipation, and insomnia (attributable to bupropion stimulation). Contraindications exist for patients with seizure disorders, uncontrolled blood pressure, or opioid dependence. Users typically experience side effect stabilization within 4–8 weeks. Bupropion also carries a black-box warning for psychiatric effects in rare cases, requiring careful screening.

Semaglutide side effects center on gastrointestinal symptoms: nausea, vomiting, diarrhea, and constipation occur in 20–40% of patients but usually diminish after 8–12 weeks as the body adapts. Rare but serious risks include thyroid C-cell tumors (in animal models at high doses), pancreatitis, and gallbladder issues. Semaglutide is contraindicated in personal or family history of medullary thyroid cancer or multiple endocrine neoplasia. PlexusDx requires baseline screening and ongoing monitoring to ensure safe, supervised treatment tailored to your medical history.

Personalized Medicine: Choosing Based on Your Genetics

Not everyone responds equally to the same weight loss medication. Genetic variants in appetite-regulating pathways—such as GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—influence how strongly your body responds to GLP-1 agonists versus combination therapies. Someone with a GLP1R variant associated with higher sensitivity may achieve better results with semaglutide at lower doses, while another person's FTO genetic profile might predict stronger response to dual-action compounds.

PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights related to peptide responsiveness—not general drug metabolism. This test, added for $99 after your first month of treatment, maps your individual biology and recommends whether Contrave's neural approach, GLP-1 monotherapy, or combination protocols align with your genetic predispositions. By anchoring treatment selection to personalized genetics, you bypass months of ineffective medication trials and move directly to the approach your body is most likely to benefit from.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide better than Contrave for weight loss?

Semaglutide generally produces greater weight loss (10–15%) than Contrave (5–9%) in clinical trials, but individual results depend on genetics, lifestyle, and medical history. PlexusDx offers compounded semaglutide injections starting at $149/month, allowing you to access GLP-1 therapy affordably while a genetic test ($99) helps confirm it's the right choice for your biology.

What is the main difference in how these medications work?

Contrave uses a central nervous system approach via naltrexone and bupropion to suppress appetite signals in the brain. Semaglutide activates GLP-1 receptors throughout the body (brain, pancreas, gut, heart) to regulate hunger, blood sugar, and digestion simultaneously. GLP-1's multi-organ mechanism often produces more substantial metabolic change.

How much does compounded semaglutide cost at PlexusDx?

PlexusDx compounded semaglutide injections start at $149/month flat, with no membership fees, no insurance required, and availability across all 50 states. Your dose may increase during treatment, but your price remains locked—a benefit of compounding pharmacy flexibility that brand-name Ozempic doesn't offer.

Are compounded GLP-1 medications as safe as brand-name versions?

Yes. PlexusDx sources compounded medications from licensed 503A compounding pharmacies, which meet strict FDA manufacturing and sterility standards. While compounded medications aren't FDA-approved as a class, they're manufactured under equivalent safety regulations and often with greater dose personalization than brand-name alternatives. All PlexusDx patients receive baseline screening and ongoing monitoring.

What does the Precision Peptide Genetic Test reveal?

PlexusDx's test identifies genetic variants in 14 metabolic pathways affecting GLP-1, GIP, FTO, and MC4R signaling—not standard pharmacogenomics. Results predict whether your body will respond strongly to GLP-1 agonists like semaglutide, combination protocols like tirzepatide, or Contrave-style approaches, helping you avoid ineffective medication trials and move directly to your best option.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves